SWG Educational Activities
EHA Meeting 2018
Education Session on Myelodysplastic Syndromes:
- The hematopoietic niche in MDS: from concept to therapeutic target
- Molecular genetics in clinical decision making
- New treatment options
Further contributions at EHA 2018 as presenter/co-author:
- U Platzbecker:
- 16 contributions (abstract numbers): S115, S152, S861, S876, S1557, S1559, PF235, PF497, PF498, PF675, PS986, PS1230, PS1240, PS1242, PS1244, PS1245
- 16 contributions (abstract numbers): S115, S152, S861, S876, S1557, S1559, PF235, PF497, PF498, PF675, PS986, PS1230, PS1240, PS1242, PS1244, PS1245
- P Fenaux:
- 10 contributions (abstract numbers): S1557, S1558, PF481, PF484, PF703, PS1233, PS1239, PS1244, PS1245, PB2100
Clinical Trials
Start of the BERGAMO trial:
A phase II study evaluating the efficacy and safety of Bemcentinib in patients with MDS or ALM failing standard of care therapy – BERGAMO trial within the EMSCO network involving the German, French, Dutch and Italian MDS study groups.
Back